atomoxetine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives	256	83015-26-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: LY139603 strattera atomoxetine tomoxetine (-)-Tomoxetine atomoxetine hydrochloride tomoxetine hydrochloride atomoxetine HCl tomoxetine HCl	A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER. Molecular weight: 255.36 Formula: C17H21NO CLOGP: 3.94 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 21.26 ALOGS: -4.82 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

LY139603
strattera
atomoxetine
tomoxetine
(-)-Tomoxetine
atomoxetine hydrochloride
tomoxetine hydrochloride
atomoxetine HCl
tomoxetine HCl

A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Molecular weight: 255.36
Formula: C17H21NO
CLOGP: 3.94
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 21.26
ALOGS: -4.82
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
80	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	27.80 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	8.39 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	94 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.85 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 26, 2002	FDA	LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	204.75	19.59	124	7752	56258	46621928
Prescribed overdose	175.13	19.59	66	7810	10383	46667803
Tic	114.38	19.59	29	7847	1207	46676979
Abnormal behaviour	99.40	19.59	55	7821	21003	46657183
Aggression	98.13	19.59	56	7820	22688	46655498
Irritability	83.23	19.59	55	7821	28891	46649295
Tachycardia	79.87	19.59	91	7785	99531	46578655
Crying	70.23	19.59	44	7832	21097	46657089
Suicide attempt	69.03	19.59	64	7812	54972	46623214
Agitation	68.65	19.59	64	7812	55351	46622835
Depression	62.91	19.59	107	7769	169997	46508189
Attention deficit hyperactivity disorder	60.39	19.59	20	7856	2152	46676034
Intentional self-injury	57.80	19.59	41	7835	24125	46654061
Disturbance in attention	52.24	19.59	43	7833	31517	46646669
Overdose	49.91	19.59	73	7803	101906	46576280
Raynaud's phenomenon	44.42	19.59	14	7862	1286	46676900
Myocarditis	44.32	19.59	23	7853	7716	46670470
Psychomotor hyperactivity	42.32	19.59	24	7852	9589	46668597
Mania	42.23	19.59	25	7851	10821	46667365
Somnolence	42.18	19.59	86	7790	156435	46521751
Intentional overdose	40.05	19.59	52	7824	64892	46613294
Electrocardiogram QT prolonged	39.57	19.59	46	7830	51279	46626907
Dystonia	38.81	19.59	24	7852	11233	46666953
Trichotillomania	38.74	19.59	8	7868	130	46678056
Impulsive behaviour	38.35	19.59	13	7863	1502	46676684
Anxiety	37.73	19.59	90	7786	181867	46496319
Anger	37.68	19.59	24	7852	11828	46666358
Supine hypertension	36.60	19.59	7	7869	75	46678111
Obsessive-compulsive disorder	35.35	19.59	15	7861	3200	46674986
Aspartate aminotransferase increased	35.14	19.59	54	7822	78646	46599540
Seizure	34.78	19.59	69	7807	122985	46555201
Loss of consciousness	34.66	19.59	64	7812	108174	46570012
Bipolar I disorder	34.22	19.59	12	7864	1534	46676652
Oppositional defiant disorder	33.91	19.59	6	7870	40	46678146
Educational problem	33.02	19.59	8	7868	275	46677911
Mydriasis	32.63	19.59	21	7855	10532	46667654
Heart rate increased	31.55	19.59	50	7826	74741	46603445
Mood swings	30.84	19.59	24	7852	16228	46661958
Renal tubular acidosis	30.18	19.59	11	7865	1572	46676614
Piloerection	28.32	19.59	7	7869	262	46677924
Thinking abnormal	26.62	19.59	18	7858	9796	46668390
Drug screen positive	26.48	19.59	13	7863	3878	46674308
Alanine aminotransferase increased	25.46	19.59	50	7826	88401	46589785
Liver injury	24.80	19.59	21	7855	15980	46662206
Dysmenorrhoea	24.62	19.59	12	7864	3526	46674660
Mood altered	24.23	19.59	19	7857	12988	46665198
Psychotic disorder	23.97	19.59	24	7852	22597	46655589
Social avoidant behaviour	23.96	19.59	11	7865	2828	46675358
Insomnia	23.46	19.59	71	7805	164853	46513333
Emotional disorder	22.95	19.59	18	7858	12306	46665880
Pneumonia	22.93	19.59	18	7858	376302	46301884
Feeling abnormal	22.86	19.59	59	7817	125001	46553185
Personality change	22.80	19.59	13	7863	5245	46672941
Merycism	21.63	19.59	5	7871	140	46678046
Rheumatoid arthritis	21.30	19.59	7	7869	240208	46437978
Generalised tonic-clonic seizure	20.38	19.59	24	7852	27098	46651088
Lymphocytic hypophysitis	20.36	19.59	5	7871	182	46678004
Diarrhoea	20.25	19.59	40	7836	559562	46118624

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	637.00	23.00	320	13896	35794	29902468
Tic	573.54	23.00	143	14073	1889	29936373
Aggression	549.76	23.00	292	13924	36615	29901647
Prescribed overdose	492.37	23.00	176	14040	8385	29929877
Abnormal behaviour	345.55	23.00	190	14026	25433	29912829
Anger	257.49	23.00	119	14097	11001	29927261
Irritability	233.55	23.00	142	14074	22908	29915354
Crying	201.95	23.00	82	14134	5527	29932735
Intentional self-injury	186.79	23.00	102	14114	13430	29924832
Testicular pain	170.64	23.00	60	14156	2712	29935550
Psychomotor hyperactivity	165.72	23.00	80	14136	8144	29930118
Oppositional defiant disorder	158.14	23.00	37	14179	365	29937897
Agitation	132.26	23.00	145	14071	53928	29884334
Homicidal ideation	127.86	23.00	47	14169	2416	29935846
Mood swings	126.48	23.00	65	14151	7561	29930701
Urinary hesitation	120.10	23.00	44	14172	2240	29936022
Disturbance in attention	118.39	23.00	92	14124	22037	29916225
Suicide attempt	116.04	23.00	113	14103	36584	29901678
Ejaculation disorder	116.04	23.00	35	14181	965	29937297
Impulsive behaviour	111.33	23.00	40	14176	1925	29936337
Attention deficit hyperactivity disorder	110.42	23.00	39	14177	1785	29936477
Acute kidney injury	109.23	23.00	5	14211	273837	29664425
Anxiety	104.13	23.00	167	14049	89704	29848558
Heart rate increased	101.93	23.00	108	14108	38613	29899649
Depressed mood	98.10	23.00	74	14142	16955	29921307
Death	97.45	23.00	25	14191	357258	29581004
Pneumonia	95.87	23.00	21	14195	334285	29603977
Mood altered	91.70	23.00	54	14162	8196	29930066
Depression	91.30	23.00	158	14058	90279	29847983
Hallucination, auditory	90.64	23.00	57	14159	9732	29928530
Bruxism	89.72	23.00	31	14185	1328	29936934
Somnolence	88.62	23.00	162	14054	96601	29841661
Decreased eye contact	85.63	23.00	23	14193	412	29937850
Insomnia	85.13	23.00	156	14060	93180	29845082
Drug screen positive	77.24	23.00	39	14177	4368	29933894
Mania	76.57	23.00	50	14166	9104	29929158
Palpitations	73.41	23.00	85	14131	33488	29904774
Psychotic disorder	73.17	23.00	69	14147	21446	29916816
Educational problem	72.98	23.00	19	14197	300	29937962
Dystonia	71.43	23.00	49	14167	9678	29928584
Mydriasis	70.35	23.00	41	14175	6102	29932160
Alanine aminotransferase increased	70.04	23.00	126	14090	74150	29864112
Product substitution issue	67.73	23.00	48	14168	9987	29928275
Self-injurious ideation	66.51	23.00	26	14190	1583	29936679
Tachycardia	64.36	23.00	121	14095	73618	29864644
Aspartate aminotransferase increased	62.88	23.00	110	14106	63312	29874950
Feeling abnormal	59.61	23.00	101	14115	56655	29881607
Electrocardiogram QT prolonged	59.47	23.00	79	14137	35756	29902506
Seizure	58.44	23.00	138	14078	98337	29839925
Anaemia	57.63	23.00	14	14202	207978	29730284
Sepsis	57.21	23.00	3	14213	146392	29791870
Dyskinesia	54.07	23.00	59	14157	21775	29916487
Diarrhoea	53.65	23.00	48	14168	334055	29604207
Penile discharge	53.34	23.00	11	14205	56	29938206
Retching	52.34	23.00	34	14182	6134	29932128
Blood alkaline phosphatase increased	51.60	23.00	69	14147	31418	29906844
Emotional disorder	50.53	23.00	31	14185	5063	29933199
Suicidal behaviour	49.30	23.00	20	14196	1342	29936920
Choreoathetosis	48.96	23.00	18	14198	925	29937337
Nervousness	48.31	23.00	42	14174	11746	29926516
Dysuria	45.82	23.00	55	14161	22486	29915776
Trismus	44.60	23.00	22	14194	2343	29935919
Generalised tonic-clonic seizure	43.55	23.00	50	14166	19501	29918761
Affect lability	42.30	23.00	24	14192	3394	29934868
Headache	40.93	23.00	183	14033	182123	29756139
Social avoidant behaviour	40.63	23.00	22	14194	2841	29935421
Gilbert's syndrome	40.37	23.00	8	14208	32	29938230
Growth retardation	39.75	23.00	18	14198	1582	29936680
Screaming	39.61	23.00	17	14199	1314	29936948
Obsessive-compulsive disorder	38.04	23.00	24	14192	4117	29934145
Enuresis	37.98	23.00	18	14198	1756	29936506
Blood bilirubin increased	36.86	23.00	64	14152	36572	29901690
Tearfulness	36.65	23.00	17	14199	1579	29936683
Sexual dysfunction	36.60	23.00	27	14189	5974	29932288
General physical health deterioration	36.22	23.00	3	14213	99941	29838321
Trichotillomania	36.14	23.00	8	14208	60	29938202
Paranoia	35.24	23.00	33	14183	10155	29928107
Renal failure	35.05	23.00	9	14207	128957	29809305
Thinking abnormal	34.90	23.00	25	14191	5286	29932976
Thrombocytopenia	34.60	23.00	11	14205	137033	29801229
Hepatic enzyme increased	34.34	23.00	59	14157	33435	29904827
Pallor	34.28	23.00	46	14170	21003	29917259
Negativism	34.12	23.00	11	14205	379	29937883
Coordination abnormal	33.98	23.00	28	14188	7277	29930985
Panic attack	33.70	23.00	30	14186	8651	29929611
Apathy	33.49	23.00	26	14190	6206	29932056
Personality change	33.36	23.00	23	14193	4577	29933685
Sleep disorder	31.76	23.00	48	14168	24431	29913831
Loss of consciousness	31.59	23.00	96	14120	79279	29858983
Physical assault	31.26	23.00	14	14202	1199	29937063
Abdominal pain upper	31.10	23.00	82	14134	62469	29875793
Fight in school	30.92	23.00	5	14211	3	29938259
Decreased appetite	30.30	23.00	146	14070	149764	29788498
Amphetamines positive	29.92	23.00	7	14209	69	29938193
Appendicitis	29.52	23.00	24	14192	6120	29932142
Respiratory failure	29.38	23.00	6	14210	100636	29837626
Cardiac failure	28.90	23.00	3	14213	83415	29854847
Tourette's disorder	28.82	23.00	7	14209	82	29938180
Repetitive speech	28.08	23.00	7	14209	92	29938170
Raynaud's phenomenon	27.78	23.00	9	14207	315	29937947
Syncope	27.74	23.00	96	14120	84807	29853455
Sedation	26.99	23.00	36	14180	16337	29921925
Hyperhidrosis	26.55	23.00	81	14135	67009	29871253
Abdominal discomfort	26.35	23.00	66	14150	48725	29889537
Pyrexia	25.98	23.00	64	14152	294425	29643837
Drug ineffective	25.62	23.00	260	13956	340127	29598135
Asthenia	25.61	23.00	41	14175	221249	29717013
Hostility	25.18	23.00	11	14205	888	29937374
Pyromania	25.04	23.00	6	14210	66	29938196
Hypotension	24.31	23.00	36	14180	200529	29737733
Oedema peripheral	24.15	23.00	10	14206	105822	29832440
Myocardial infarction	23.99	23.00	15	14201	125610	29812652
Dyspnoea	23.86	23.00	80	14136	333215	29605047
Dysphoria	23.70	23.00	14	14202	2134	29936128
Semen analysis abnormal	23.01	23.00	5	14211	34	29938228

Pharmacologic Action:

Source	Code	Description
ATC	N06BA09	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
FDA MoA	N0000000102	Norepinephrine Uptake Inhibitors
FDA EPC	N0000175695	Norepinephrine Reuptake Inhibitor
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
CHEBI has role	CHEBI:35469	thymoanaleptics
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Attention deficit hyperactivity disorder	indication	406506008
Delay when starting to pass urine	contraindication	5972002
Priapism	contraindication	6273006	DOID:9286
Suicidal thoughts	contraindication	6471006
Sinus tachycardia	contraindication	11092001
Bipolar disorder	contraindication	13746004	DOID:3312
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Myocardial infarction	contraindication	22298006	DOID:5844
Feeling agitated	contraindication	24199005
Orthostatic hypotension	contraindication	28651003
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Feeling irritable	contraindication	55929007
Aggressive behavior	contraindication	61372001
Cerebrovascular disease	contraindication	62914000	DOID:6713
Psychotic disorder	contraindication	69322001
Cardiomyopathy	contraindication	85898001	DOID:0050700
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Disease of liver	contraindication	235856003	DOID:409
Raynaud's phenomenon	contraindication	266261006
Retention of urine	contraindication	267064002
Pheochromocytoma	contraindication	302835009
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.32	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	8.69	CHEMBL	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Kd	5.97	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.68	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Kd	8.05	CHEMBL
Kir3.1/Kir3.2	Ion channel	P48051 P48549	KCNJ3_HUMAN KCNJ6_HUMAN		IC50	4.48	WOMBAT-PK
Kir3.1/Kir3.4	Ion channel	P48544 P48549	KCNJ3_HUMAN KCNJ5_HUMAN		IC50	4.84	WOMBAT-PK
G protein-activated inward rectifier potassium channel 2	Ion channel	P48051	KCNJ6_HUMAN		IC50	4.28	WOMBAT-PK
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	4.77	WOMBAT-PK
Krueppel-like factor 10	Unclassified	Q13118	KLF10_HUMAN		IC50	4	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	7.37	CHEMBL
Transporter	Transporter		Q63380_RAT		Ki	8.40	CHEMBL
Transporter	Transporter		Q9WTR4_RAT		Ki	9.15	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	5.85	CHEMBL

External reference:

ID	Source
ASW034S0B8	UNII
D02574	KEGG_DRUG
82248-59-7	SECONDARY_CAS_RN
4021364	VANDF
4024296	VANDF
C0076823	UMLSCUI
CHEBI:127342	CHEBI
CHEMBL641	ChEMBL_ID
CHEMBL1702	ChEMBL_ID
54841	PUBCHEM_CID
DB00289	DRUGBANK_ID
D000069445	MESH_DESCRIPTOR_UI
5354	INN_ID
7118	IUPHAR_LIGAND_ID
353103	RXNORM
17042	MMSL
192105	MMSL
45567	MMSL
d04827	MMSL
009862	NDDF
009863	NDDF
407037005	SNOMEDCT_US
407038000	SNOMEDCT_US
412577007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3227	CAPSULE	10 mg	ORAL	NDA	37 sections
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3228	CAPSULE	25 mg	ORAL	NDA	37 sections
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3229	CAPSULE	40 mg	ORAL	NDA	37 sections
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3238	CAPSULE	18 mg	ORAL	NDA	37 sections
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3239	CAPSULE	60 mg	ORAL	NDA	37 sections
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3250	CAPSULE	80 mg	ORAL	NDA	37 sections
Strattera	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3251	CAPSULE	100 mg	ORAL	NDA	37 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3542	CAPSULE	10 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3543	CAPSULE	18 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3544	CAPSULE	25 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3545	CAPSULE	40 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3546	CAPSULE	60 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3547	CAPSULE	80 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3548	CAPSULE	100 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2260	CAPSULE	10 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2261	CAPSULE	18 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2262	CAPSULE	25 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2263	CAPSULE	40 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2264	CAPSULE	60 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2265	CAPSULE	80 mg	ORAL	ANDA	32 sections
Atomoxetine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2266	CAPSULE	100 mg	ORAL	ANDA	32 sections
Atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6908	CAPSULE	40 mg	ORAL	ANDA	31 sections
STRATTERA	HUMAN PRESCRIPTION DRUG LABEL	1	16590-337	CAPSULE	10 mg	ORAL	NDA	35 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-755	CAPSULE	10 mg	ORAL	ANDA	33 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-756	CAPSULE	18 mg	ORAL	ANDA	33 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-757	CAPSULE	25 mg	ORAL	ANDA	33 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-758	CAPSULE	40 mg	ORAL	ANDA	33 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-759	CAPSULE	60 mg	ORAL	ANDA	33 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-760	CAPSULE	80 mg	ORAL	ANDA	33 sections
atomoxetine	HUMAN PRESCRIPTION DRUG LABEL	1	16714-761	CAPSULE	100 mg	ORAL	ANDA	33 sections